About SIGA Technologies, Inc.
https://www.siga.comSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
CEO
Diem Nguyen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : A+
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.91M
Value:$26.3M
BLACKROCK, INC.
Shares:3.53M
Value:$23.69M
VANGUARD GROUP INC
Shares:2.66M
Value:$17.85M
Summary
Showing Top 3 of 232
About SIGA Technologies, Inc.
https://www.siga.comSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.62M ▼ | $11.84M ▲ | $-6.37M ▼ | -242.97% ▼ | $-0.09 ▼ | $-8.21M ▼ |
| Q2-2025 | $81.12M ▲ | $9.89M ▲ | $35.48M ▲ | 43.74% ▲ | $0.5 ▲ | $47.41M ▲ |
| Q1-2025 | $7.04M ▼ | $9.14M ▼ | $-408.22K ▼ | -5.8% ▼ | $-0.01 ▼ | $-2.12M ▼ |
| Q4-2024 | $81.47M ▲ | $10.25M ▲ | $45.76M ▲ | 56.17% ▲ | $0.64 ▲ | $57.22M ▲ |
| Q3-2024 | $10.01M | $7.85M | $1.34M | 13.43% | $0.02 | $542.09K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $171.96M ▼ | $231.6M ▼ | $28.12M ▲ | $203.48M ▼ |
| Q2-2025 | $182.46M ▲ | $235.33M ▼ | $26.02M ▼ | $209.31M ▼ |
| Q1-2025 | $162.27M ▲ | $247.07M ▲ | $30.93M ▲ | $216.13M ▲ |
| Q4-2024 | $155.4M ▲ | $244.34M ▲ | $28.53M ▲ | $215.8M ▲ |
| Q3-2024 | $99.27M | $195.35M | $25.91M | $169.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.37M ▼ | $-9.81M ▼ | $-289.58K ▼ | $-403.48K ▲ | $-10.51M ▼ | $-10.1M ▼ |
| Q2-2025 | $35.48M ▲ | $63.08M ▲ | $-1 ▲ | $-42.89M ▼ | $20.19M ▲ | $63.08M ▲ |
| Q1-2025 | $-408.22K ▼ | $7.06M ▼ | $-24.89K ▼ | $-166.19K ▼ | $6.87M ▼ | $7.04M ▼ |
| Q4-2024 | $45.76M ▲ | $56.31M ▲ | $-17.84K ▲ | $-161.76K ▲ | $56.13M ▲ | $56.29M ▲ |
| Q3-2024 | $1.34M | $-7.38M | $-22.43K | $-274.13K | $-7.68M | $-7.41M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product Sales and Supportive Services | $80.00M ▲ | $10.00M ▼ | $80.00M ▲ | $0 ▼ |
 Research and Development | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 CANADA | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 NonUS | $10.00M ▲ | $0 ▼ | $0 ▲ | $10.00M ▲ |
 UNITED STATES | $70.00M ▲ | $80.00M ▲ | $0 ▼ | $0 ▲ |
 Asia Pacific | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 EMEA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Diem Nguyen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : A+
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.91M
Value:$26.3M
BLACKROCK, INC.
Shares:3.53M
Value:$23.69M
VANGUARD GROUP INC
Shares:2.66M
Value:$17.85M
Summary
Showing Top 3 of 232